A more efficient DNA technology to detect and treat infectious diseases and cancer has been developed by researchers at the Institute of Bioengineering and Nanotechnology (IBN) of A*STAR.
The researchers improved on existing technologies to create a modified single-stranded DNA molecule called aptamer. DNA aptamers are ideal for pharmaceutical applications because they can specifically bind to any molecular target in the body such as proteins, viruses, bacteria and cells.
Once DNA aptamers are artificially generated for each target, they will bind to it and inhibit its activity. This makes DNA aptamers a promising technology for disease detection and drug delivery. But no DNA aptamers have been approved for clinical use yet because current aptamers do not bind well to molecular targets and are easily digested by enzymes.
“To overcome these challenges, we have created a DNA aptamer with strong binding ability and stability with superior efficacy. We hope to use our DNA aptamers as the platform technology for diagnostics and new drug development,” said IBN Executive Director Professor Jackie Y. Ying.
This study, led by IBN Principal Research Scientist and Team Leader Dr Ichiro Hirao, was recently published in the journal, Scientific Reports.
To tackle the weak binding problem, the research team added a new artificial component called unnatural base to a standard DNA aptamer, which typically has four components. The addition of the fifth component greatly enhanced the binding ability to the molecular target by 100 times as compared to conventional DNA aptamers. Furthermore, to prevent the aptamer from being digested easily by enzymes, a unique and small DNA called ‘mini-hairpin DNA’ was added to the DNA aptamer.
Dr Hirao explained, “The mini-hairpin DNAs have an unusually stable and compact stem-loop structure, like a hairpin, of small DNA fragments. Their structure strongly resists the digestive enzymes, so I added them to specific positions on the DNA aptamer to act as a protective shield. Usually DNAs are digested within one hour in blood at body temperature. With the mini-hairpin DNA, our DNA aptamers can survive for days instead of hours. This is important for pharmaceutical applications, which require the therapeutic to remain in the body for a longer period.”
If successfully commercialized, DNA aptamers could replace or complement the existing use of antibodies in drugs for targeted disease treatment. Like aptamers, antibodies bind to targets in the body, but often cause undesirable immune response and are not easy to mass produce with high quality.
“We can now generate very promising DNA aptamers for clinical use. Our aptamers are more efficient, and lower in cost and toxicity compared to conventional methods. The next step of our research is to use the aptamers to detect and deactivate target molecules and cells that cause infectious diseases, such as dengue, malaria and Methicillin-resistant Staphylococcus aureus, as well as cancer,” added Dr Hirao.
The Latest on: DNA technology
via Google News
The Latest on: DNA technology
- El Dorado County Thief Caught One Year After Crime Highlights Need For Rapid DNA Testingon January 21, 2021 at 10:51 pm
A thief who got away with $50,000 in cash in El Dorado County was tracked down an entire year after the crime. It's a situation that highlights the need for rapid DNA testing.
- Applied DNA Sciences (NASDAQ:APDN) Stock Rating Upgraded by Zacks Investment Researchon January 21, 2021 at 10:18 pm
Applied DNA Sciences (NASDAQ:APDN) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Zacks.com ...
- Applied DNA Promotes Judith Murrah to Chief Operating Officeron January 20, 2021 at 9:53 pm
Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced the promotion of Chief Information Officer Judith Murrah ...
- DNA technology ‘ready, willing and able’ to provide transparency to meat productson January 20, 2021 at 2:41 pm
DNA technology 'ready, willing and able' to provide transparency to meat products We know that today's consumer expects increased ...
- DNA technology ‘ready, willing and able’ to deliver transparency to meat productson January 20, 2021 at 8:16 am
DNA testing can help bolster confidence in meat products, believes traceability expert IdentiGEN. We know that today’s consumers expect heightened levels of traceability – particularly when it comes ...
- Recombinant DNA Technology Market Is Booming Worldwide (2021-2030) With COVID-19 Updates | Profacgen, Monsanto Companyon January 19, 2021 at 3:22 pm
MarketResearch.Biz –:An extensive and elaborate primary research on Global Recombinant DNA | eTurboNews | Trends | Travel News Online | ...
- Twist Bioscience Signs Two Biopharma Technology Agreements to Enable Novel Therapeutics Discoveryon January 19, 2021 at 10:00 am
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its sili ...
- Recombinant DNA (rDNA) Technology Market : Business overview, Upcoming Trends and Top Company Analysis Forecast By 2025on January 19, 2021 at 12:25 am
The report offers overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts. Recombinant DNA ...
- DNA Technology Helped Identify Two Cold Case Suspects in 2020 | WDVM25 and DCW50on January 18, 2021 at 3:39 pm
DNA Technology Helped Identify Two Cold Case Suspects in 2020 | WDVM25 and DCW50 RESTON, Va. (WDVM) - Nearly 30 years ago, 24800 Old ...
- Can New DNA Technology Help Track Down Killer Of Little Girl Who Inspired Amber Alert System, 25 Years Later?on January 14, 2021 at 10:39 am
A quarter-century after the murder of a 9-year-old Texas girl — a case that subsequently inspired the nationwide AMBER Alert system in missing children cases — investigators are still on the hunt for ...
via Bing News